Anti Cd 20 Ocrevus denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy Before Ocrevus

Step-therapy (also called "fail-first") denials require a patient to try and fail one or more lower-cost or lower-tier disease-modifying therapies before Aetna will authorize Ocrevus (ocrelizumab). For MS, this typically means demonstrating inadequate response to, or intolerance of, interferon-beta agents, glatiramer acetate, oral DMTs, or other platform therapies listed in Aetna's step-therapy protocol.

Step-therapy denials for Ocrevus are frequently overturned on appeal for two reasons: (1) the patient has already tried and failed the required prior therapies, or (2) Ocrevus is sought for primary progressive MS, for which many step-therapy alternatives lack FDA approval — making the step requirement clinically inapplicable.

## Federal Appeal Rights

• Step-therapy exception: Many states and employer plans have step-therapy exception laws or policies requiring the plan to waive the step requirement if prior therapy has failed, is contraindicated, or is clinically inappropriate. File this first — it is often faster than a full appeal.
• Internal appeal: Under ERISA §503 or ACA rules, you may appeal the step-therapy requirement as an adverse benefit determination. The denial letter will state the deadline.
• External review: Under ACA §2719, external review by an IRO is available after exhausting internal remedies. IROs evaluate whether the step-therapy protocol is consistent with generally accepted standards of medical practice for this patient's clinical situation.
• Expedited review: Available when delay creates serious health risk — for example, rapidly worsening disease activity during a mandated trial of an ineffective agent.

## What to Gather

1. Prior therapy documentation — for every DMT Aetna's protocol requires as a first step, provide: (a) dates of use, (b) documented clinical response or lack thereof (MRI changes, relapse activity, functional decline), and (c) reason for discontinuation. This is the single most important category. 2. Contraindication or intolerance records — if a required step agent was not tried because of a documented clinical reason (allergy, prior adverse event, comorbidity, lack of approval for the patient's MS subtype), document this explicitly in the chart and in the prescriber letter. 3. MS subtype confirmation — for PPMS patients, document that the required step agents are not FDA-approved for primary progressive MS. This is often sufficient on its own to waive the step requirement. 4. Disease progression during any step trial — if the patient's condition worsened while on a required prior therapy, document this with MRI comparisons and neurologist notes. 5. Prescriber step-therapy exception letter — the neurologist should address each required step agent and explain why moving directly to Ocrevus is medically necessary.

## Criteria-Mapping Structure

| Step-Therapy Requirement | Documentation | |---|---| | Step agent A: tried and failed | Medication history; MRI or relapse data during trial | | Step agent B: contraindicated or not approved for subtype | Prescriber letter; FDA label for step agent | | Patient's MS subtype (PPMS) exempts from step | Diagnosis confirmation; FDA label for Ocrevus | | Harm from continued step trial | Neurologist note documenting progression |

If the patient has PPMS, lead the letter with the FDA-indication argument — it is the cleanest path. If the patient has relapsing MS and has already tried required agents, lead with the documented failure history.